EW stock: buy or sell?
November 15th, 2019
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally.
Should I buy EW stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
These 2 buy setups are elegible for Edwards Lifesciences stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Edwards Lifesciences stock a buy?
Banks and financial institutions post stock ratings everyday.At Stocks2.com, we detected 15 ratings published for EW stock in the last 30 days. The general sentiment of these ratings is bullish for EW stock, with 12 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-6||Wells Fargo & Co||n/a||Outperform|
|2019-9-23||Piper Jaffray Companies||n/a||Overweight|
|2019-7-24||Wells Fargo & Co||n/a||Outperform|
|2019-7-24||JPMorgan Chase & Co.||n/a||Neutral|
|2019-7-24||Jefferies Financial Group||n/a||Buy|
|2019-7-24||Credit Suisse Group||n/a||Outperform|
|2019-7-24||BMO Capital Markets||n/a||Outperform|
|2019-7-24||Bank of America||Buy||Buy|
EW stock analysis
After topping to all time highs yesterday, Edwards Lifesciences rose 2.11% to $245.64.
After topping to all time highs yesterday, Edwards Lifesciences rose 2.11% to $245.64. Since SMA50d and SMA100d crossed up on July, EW price climbed $54.46 per share (28.49%). Yesterday, EW hit a new all time high, pushing higher than on Wednesday tops. Check different trading setups that use ATHs as triggers. On Oct/9 EW price bounced up over the SMA of 50 days demonstrating to be a significant support for this stock.
Edwards Lifesciences ended this week at $245.64 after marking a new all time high ($245.95) and climbed a brilliant 4.90%. Late September EW rocketed a superb 5.28% in just one week.
Edwards Lifesciences stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, EW might consolidate in a flat-base, waiting to break out over or down under . Late December 2018 EW price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
EW stock price history
EW stock went public on March 27th, 2000 with a price of $3.811. Since then, EW stock grew a 6,347.20%, with an average of 334.10% per year. If you had invested right after EW's IPO a $1,000 in EW stock in 2000, it would worth $63,472.00 today.
1: Adjusted price after possible price splits or reverse-splits.
EW stock historical price chart
EW stock reached all-time highs yesterday with a price of $245.95.
EW stock price target is $227.30Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' EW stock price predictions in the hope that they will be met as they may be wrong and not met. We detected 14 price predictions for EW stock published in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-6||Wells Fargo & Co||Raises Target||$220.00||$250.00||13.6%|
|2019-9-23||Piper Jaffray Companies||Initiates||n/a||$240.00||-|
|2019-7-24||Wells Fargo & Co||Reiterates||$207.00||$220.00||6.3%|
|2019-7-24||Raymond James||Raises Target||$200.00||$232.00||16%|
|2019-7-24||Morgan Stanley||Raises Target||$210.00||$228.00||8.6%|
|2019-7-24||JPMorgan Chase & Co.||Raises Target||$190.00||$225.00||18.4%|
|2019-7-24||Jefferies Financial Group||Reiterates||$210.00||$245.00||16.7%|
|2019-7-24||Credit Suisse Group||Reiterates||$221.00||$226.00||2.3%|
|2019-7-24||BMO Capital Markets||Reiterates||$204.00||$224.00||9.8%|
|2019-7-24||Bank of America||Reiterates||$215.00||$225.00||4.7%|
|2019-7-16||Morgan Stanley||Raises Target||$197.00||$210.00||6.6%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter publishing its last earnings report on April, Edwards Lifesciences . As soon as we get its actual EPS from the earnings report, we will update this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Edwards Lifesciences annual sales soared a shining 8.37% to $3,722.80 M dollars from $3,435.30 marked in 2017. On the other hand, its earnings margin (compared to sales) appreciated to 19.40%, that is $722.20 million. Edwards Lifesciences fiscal year ends in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Edwards Lifesciences TTM sales up to March 2019 were $3,821.00 and earnings $765.30 million USD. If we compare this TTM figures with the last reported annuality, we can review Edwards Lifesciences business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, gained a slightly fine 2.64%. Regarding profit margin, Edwards Lifesciences remained steady 0.63% to 19.40%
|2013||$2,050 M||-||$392 M19.1%||-|
|2014||$2,323 M||13.31%||$811 M34.9%||107.07%|
|2015||$2,494 M||7.35%||$495 M19.8%||-38.98%|
|2016||$2,964 M||18.85%||$570 M19.2%||15.07%|
|2017||$3,435 M||15.91%||$584 M17.0%||2.48%|
|2018||$3,723 M||8.37%||$722 M19.4%||23.75%|
|TTM||$3,821 M||2.64%||$765 M20.0%||5.97%|
Quarterly financial resultsEdwards Lifesciences posted $993.00 million in revenues for 2019-Q1, a 1.56% improvement compared to previous quarter. Reported quarter income marked $249.70 million with a profit margin of 25.15%. Profit margin skyrocketed a 24.43% compared to previous quarter when profit margin was 0.72%. When comparing sales to same quarter last year, Edwards Lifesciences sales marked a brilliant growth and boosted a 10.97%. Looking back to recent quarterly results, Edwards Lifesciences posted 2 positive quarters in a row.
|2017-Q2||$842 M||-||$186 M22.1%||-|
|2017-Q3||$822 M||-2.41%||$170 M20.7%||-8.60%|
|2017-Q4||$889 M||8.16%||$-3 M-0.3%||-101.65%|
|2018-Q1||$895 M||0.71%||$207 M23.1%||-7,478.57%|
|2018-Q2||$944 M||5.46%||$283 M30.0%||36.83%|
|2018-Q3||$907 M||-3.93%||$226 M24.9%||-20.09%|
|2018-Q4||$978 M||7.84%||$7 M0.7%||-96.90%|
|2019-Q1||$993 M||1.56%||$250 M25.1%||3,467.14%|
Edwards Lifesciences ownershipWhen you are planning to buy a stock, it's worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Edwards Lifesciences, 3.94% of all outstanding shares are owned by its staff.
In case of Edwards Lifesciences stock, 0.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for EW stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Edwards Lifesciences:
|Market cap||$51.2 B||$58.8 B||$941.6 M||$3.6 B||$682.4 M|
|Total shares||208.6 M||1,390.0 M||37.5 M||20.7 M||19.9 M|
|Float shares||207.1 M||1,390.0 M||36.0 M||19.2 M||16.2 M|
|- Institutional holdings (%)||0.0%||93.4%||72.1%||93.5%||77.8%|
|- Insider holdings (%)||3.9%||0.2%||3.8%||7.1%||18.5%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, November 15th, 2019|
|Day range||$241.54 - $245.95|
|Average true range||$4.28|
|50d mov avg||$226.74|
|100d mov avg||$216.95|
|200d mov avg||$198.38|
Edwards Lifesciences performanceTo better understand Edwards Lifesciences performance you must becnhmark its gains with other related stocks in same sector or industry. For Edwards Lifesciences, the benchmark is made against Boston Scientific, CryoLife, ICU Medical, LeMaitre Vascular, Medtronic and Merit Medical Systems.
|MMSIMerit Medical Sys...||-26.92%||-51.83%||-56.85%|
Edwards Lifesciences competitorsOne check before trading any stock is to review a list of its competitors, in this case for Edwards Lifesciences. We chose 6 companies as Edwards Lifesciences competitors as they are in the same industry or have similar market objectives.
- Boston Scientific (BSX)
- CryoLife (CRY)
- ICU Medical (ICUI)
- LeMaitre Vascular (LMAT)
- Medtronic (MDT)
- Merit Medical Systems (MMSI)
Latest EW stock news
- Seeking AlphaEdwards Lifesciences Beats, Raises And Surges: AnalysisJuly 24, 2019
- Seeking AlphaEdwards Lifesciences: A Med-Tech Stock Staying Strong For A ReasonMay 15, 2019
- Seeking AlphaEdwards Lifesciences: Assessing The Next MovesMay 1, 2019
- Seeking AlphaEdwards Lifesciences: It's Expensive, But It's Recession-ProofFebruary 20, 2019
- Seeking AlphaEdwards Lifesciences: Good For The Heart And Your PortfolioAugust 17, 2018